Janus Global Life Sciences Fund has been named best Global Health/Biotechnology Fund for delivering consistently strong risk-adjusted performance, relative to peers, over the last three, five and ten years
(Class I, D and D shares respectively)*
Managed by Andy Acker, the Fund leverages the power of Janus' deep fundamental research to seek the most compelling investment opportunities across the health care spectrum and around the world, with a strong focus on businesses that address unmet medical needs or make the health care system more efficient. We believe the combination of rigorous, bottom-up research and disciplined portfolio construction will lead to consistently strong results relative to both the health care sector and the broader equity market. The Fund is balanced across the sub-sectors of health care and diversified across market cap segments and geographies.